TRIAL DETAIL

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.

Drug:
Trial Name:
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
1
Start Date 05/01/2007
Age of Trial (yrs) 14.6
Treatment Phase:
Gleevec-resistant
Drug Category:
Virotherapy
Strategy:
Stimulate the immune system
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
LUD2005-003, EudraCT:2006-002015-27
Sponsor:
Ludwig Institute for Cancer Research
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:

Trial Links

Trial Results

 

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Frankfurt
Germany